Hepatitis

This pilot study is testing whether a 4-week course of two antiviral drugs—sofosbuvir plus glecaprevir/pibrentasvir—can cure chronic hepatitis C in people who have not been treated before and have only mild liver scarring. Participants who relapse after the short treatment will r…

This trial tests whether giving pegylated interferon to people with chronic hepatitis B—after they have already received an antisense oligonucleotide or small interfering RNA treatment—can clear the hepatitis B surface antigen from their blood. About 72 adults who saw a significa…

This study tests a new two-drug combination (ASC22 and Peg-IFNa) to see if it can functionally cure chronic hepatitis B. About 150 adults with low virus levels will receive the treatment. The goal is to raise the cure rate above 50% without needing lifelong medication.

This study tests a collaborative care model where pharmacists, doctors, and patient navigators work together to provide hepatitis C treatment to people who use drugs and live in supportive housing. 444 participants will be randomly assigned to either this model or usual care. The…

This study tests whether a low-barrier hepatitis C treatment program can help people in jail start and finish their medication more easily. Forty adults awaiting trial at the Rhode Island Department of Corrections will receive a 12-week course of the antiviral drug Epclusa. If re…

This early-stage trial tests a new vaccine called WGc0201 in 9 adults with chronic hepatitis B who are already on standard antiviral therapy. The vaccine is designed to boost the immune system to clear the virus, potentially leading to a functional cure. The main goal is to check…

This study looks at whether the diabetes drug pioglitazone can improve how the liver processes energy in people with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Researchers will measure liver mitochondrial function using special tracers before and after 16 weeks…

This early-stage trial is evaluating an investigational drug called ACT201, given as an injection, to see if it is safe and tolerable. The study first tests single and multiple doses in healthy volunteers, then moves to people with chronic hepatitis B whose virus is already suppr…

This trial tests whether treating hepatitis C in primary care clinics, with non-specialist doctors, works as well as the standard specialist care in Brazil. It also evaluates the use of rapid tests and self-testing to find more people with the infection. The goal is to see if a s…

This early-stage study tests a new gene therapy called PBGENE-HBV in 45 adults with chronic hepatitis B who are already on antiviral medication. The goal is to see if the treatment is safe and can help control the virus. Participants must be in good health and have no liver scarr…

This study is testing the safety and drug levels of glecaprevir/pibrentasvir, a hepatitis C treatment, in 30 pregnant women with or without HIV. The goal is to see how the drug works during pregnancy and to monitor the health of both mothers and their infants up to 10 weeks after…

This Phase 3 trial tests whether survodutide, a weekly injection, can improve liver outcomes in 1590 adults with NASH or MASH cirrhosis. Participants are randomly assigned to receive survodutide or a placebo, along with diet and exercise counseling. The study will track serious l…

This study looks at how the liver responds to food and a drug called semaglutide in people with non-alcoholic fatty liver disease (NAFLD). About 84 adults, including healthy volunteers, will take part. Researchers will check if semaglutide can reduce liver fat and damage over 30 …

This phase 3 trial tests survodutide, a weekly injection, in 1800 adults with MASH and moderate to advanced liver fibrosis. Participants receive either the drug or a placebo for up to 7 years, alongside diet and exercise advice. The goal is to see if survodutide can improve or re…

This Phase 3 study tests a drug called efruxifermin in 1,650 people with non-cirrhotic NASH/MASH and moderate liver scarring (stage 2 or 3). Participants receive either the drug or a placebo as a weekly injection. The goal is to see if the drug can reverse liver inflammation and …

This study tests two experimental drugs, ECC4703 and ECC0509, alone or together, in 160 adults with MASH (a type of fatty liver disease). The goal is to see if they can safely reduce liver fat over 12 weeks. Participants will be randomly assigned to receive the drugs or a placebo…

This study tests a new medicine called BI 3802876 in adults with compensated cirrhosis caused by MASH (a type of fatty liver disease). The main goal is to see if the drug is safe and how the body handles it. Participants receive either the drug or a placebo as an infusion, and ar…

This phase 2 trial tests an experimental drug called AHB-137 in 70 adults with chronic hepatitis B who are already on antiviral pills. The drug is given as a shot under the skin. The goal is to see if it can lower the virus to undetectable levels and allow some people to stop the…

This study tests a drug called foscenvivint in people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. Participants receive the drug once a week for 24 weeks. Researchers will check if the drug improves liver function and is safe to use.

This Phase 3 study tests an experimental drug called pegozafermin in 762 adults with liver scarring (cirrhosis) caused by MASH, a fatty liver disease. Participants receive weekly injections of the drug or a placebo for about two years. The goal is to see if the drug can improve l…

This Phase 3 trial tests whether efimosfermin alfa can improve liver fibrosis in adults with compensated cirrhosis caused by MASH (a fatty liver disease). Participants receive either the drug or a placebo via injection. The main goal is to see if liver scarring improves by at lea…

This phase 3 study tests whether an experimental drug called efimosfermin alfa can prevent serious liver complications in adults with compensated cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis). Participants receive either the drug or a placebo as a shot …

This study tests a new drug, pegozafermin, in 1,350 adults with MASH (a type of fatty liver disease) and moderate liver scarring (stage F2 or F3). The goal is to see if the drug can improve scarring or resolve liver inflammation without making the disease worse over 52 weeks. Par…

This Phase 2 trial tests an injection called AHB-137 in 60 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the drug can lower virus levels enough that patients can safely stop all treatment. The study will check if the virus stays undetec…

This Phase 2 trial tests an experimental drug called AHB-137 in 84 adults with chronic hepatitis B who are already on antiviral therapy. The goal is to see if AHB-137 can clear the hepatitis B surface antigen and keep the virus under control, potentially leading to a functional c…

This study tests two drugs, VIR-2218 and peginterferon, in 50 adults with mild chronic hepatitis B. The goal is to lower the virus level in the blood and improve the body's immune response. Participants receive injections for 6 months and are followed for over 2 years, including …

This early-stage trial is testing an experimental drug called INI-822 to see if it is safe and tolerable. It involves healthy volunteers and people with MASH, a type of fatty liver disease. The study will give different doses of the drug or a placebo to see how the body handles i…

This early-stage study tests a new drug called OPK-88006 in 30 people, first in healthy volunteers and then in those with MASH (a serious liver condition). The goal is to check safety, how the drug moves through the body, and early signs of liver improvement. Results will help de…

This trial compares two approaches for treating advanced metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity. About 120 adults with MASH and liver fibrosis will be randomly assigned to either metabolic surgery (gastric bypass or sl…

This study tests whether resmetirom, a daily pill, can reduce liver fat in people who have had a liver transplant and developed MASH (a type of fatty liver disease). About 120 participants will be randomly assigned to receive either resmetirom or a placebo for 28 weeks. The main …

This early-stage study tests a new drug called IB-001 for chronic hepatitis B. It will first check safety in up to 60 healthy volunteers, then test multiple doses in about 30 people with chronic hepatitis B. The main goal is to see if the drug is safe and how the body handles it.

This study tests a new drug called GS-4321 for chronic hepatitis delta, a serious liver infection. First, healthy volunteers will help determine safe dosing. Then, people with the disease will receive multiple doses to see if the drug can reduce virus levels and improve liver hea…

This Phase 2 trial tests a new drug called AHB-137, given alongside a hepatitis B vaccine or peginterferon, in 200 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the combination can clear the hepatitis B surface antigen (HBsAg) from the …

This early-stage study tests a single injection of AHB-137 in 32 people with chronic hepatitis B, some with mild to moderate liver dysfunction and some with normal liver function. Researchers will measure how the drug moves through the body and check for safety issues. The goal i…

This study checks if people with chronic hepatitis B who got better with the drug AHB-137 stay virus-free over time. About 200 adults who already responded to AHB-137 will be followed for years. The goal is to see if the virus stays undetectable and if liver health improves witho…

This phase 2 trial tests an injection called AHB-137 in adults with chronic hepatitis B who have not yet received treatment. The study compares AHB-137 to a placebo to see if it can lower the amount of hepatitis B virus in the blood and reduce a key marker of infection (HBsAg). P…

This early-stage trial tests an experimental drug called AT-587 in healthy adults to see if it is safe and how the body processes it. The drug is being developed as a potential treatment for hepatitis E, a liver infection that currently has no approved therapy. Participants recei…

This Phase 3 trial tests whether efimosfermin alfa can improve liver scarring and reduce inflammation in people with MASH (a type of fatty liver disease). About 1,200 adults with moderate-to-severe liver fibrosis will receive the drug or a placebo for 52 weeks. The goal is to see…

This phase 3 trial tests a drug called efimosfermin alfa in 1250 adults with MASH (a fatty liver disease) and moderate liver scarring. The main goal is to check safety and side effects. Participants will receive either the drug or a placebo, and researchers will monitor liver hea…

This study tests an experimental injection called HRS-5635 in adults with chronic hepatitis B whose virus is already controlled by daily pills. The goal is to see if the injection can help the body clear the virus so patients can safely stop all hepatitis B medications. About 540…

This Phase 3 trial tests an experimental drug called larsucosterol in 350 people with severe alcohol-associated hepatitis. The goal is to see if the drug helps patients survive for 90 days without needing a liver transplant. Participants receive either the drug or a placebo by IV…

This study looks at whether adding L-carnitine, a natural substance, to standard care can improve outcomes for critically ill adults with liver disease in the ICU. About 58 participants with conditions like liver failure or severe infections will be enrolled. Researchers will tra…

This early-stage study tests an injection called AHB-171 in healthy volunteers and people with chronic hepatitis B. The main goals are to check safety, how the body processes the drug, and whether it shows any signs of controlling the virus. About 110 participants will be enrolle…

This Phase 2 trial tests an injection called AHB-171 in 138 people with chronic hepatitis B. The goal is to see if it can lower hepatitis B surface antigen and viral DNA to very low levels, potentially leading to a functional cure. Participants include those who have never been t…

This phase II trial tests whether two experimental drugs, GST-HG131 and GST-HG141, can safely reduce hepatitis B surface antigen (HBsAg) levels in people with chronic hepatitis B. The study involves 80 adults aged 35-65. Participants receive either the drug combination or a place…

This early-stage trial is testing an experimental drug called GIGA-2339 in 48 adults with chronic hepatitis B. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either GIGA-2339 or a placebo by IV infusion, and researchers will…

This phase 3 trial tests efruxifermin, a weekly injection, in 2,150 adults with liver scarring (cirrhosis) caused by NASH/MASH, a type of fatty liver disease. Half get the drug, half get a placebo. The goal is to see if efruxifermin can prevent serious liver events like liver fai…

This study tests whether adding alcohol use disorder treatments (acamprosate and counseling) to standard liver therapy improves outcomes for people with severe alcohol-associated hepatitis. It also compares a new drug, F-652, against prednisone for liver treatment. About 216 adul…

This Phase 2 trial tests a drug called ALN-HSD, which uses gene silencing to target liver scarring in people with MASH, a fatty liver disease that can lead to cirrhosis. The study enrolls 120 adults with genetic risk factors and moderate-to-severe liver fibrosis. Researchers will…

This phase 2 trial tests a drug called efimosfermin alfa in 42 adults with liver scarring (cirrhosis) caused by fatty liver disease (MASH). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to check safety and how the drug moves through …

This study tests an experimental drug called ALN-CIDEB in adults with fatty liver conditions (MASLD or MASH). The main goal is to check safety and tolerability, and also to see if the drug can reduce liver fat. About 132 participants will receive either the drug or a placebo. Thi…

This study tests whether taking a low dose of niacin (vitamin B3) after meals can help reduce fat stored in the liver for people with metabolic fatty liver disease (MASLD). Researchers will compare niacin to a placebo in 36 adults aged 50 to 80. The goal is to see if niacin can r…

This trial tests whether giving the antiviral drug tenofovir disoproxil fumarate (TDF) to pregnant women with active hepatitis B can prevent the virus from spreading to their babies. The women take TDF from the 28th week of pregnancy until six weeks after giving birth, and all ne…

This study tests whether switching from the current drug bulevirtide to a new drug called brelovitug can better control chronic hepatitis Delta. About 120 adults who have been on bulevirtide for at least 6 months will take brelovitug for 24 weeks. The main goal is to see if the v…

This study tests whether a minimally invasive procedure called endoscopic sleeve gastroplasty (ESG), which reduces stomach size by 70%, can help reverse fatty liver disease (MASH) in people with obesity. Researchers will compare ESG plus lifestyle changes to lifestyle changes alo…

This phase 3 trial compares a new drug, brelovitug, to an existing treatment (bulevirtide) for chronic hepatitis delta, a serious liver infection. About 172 adults with the infection will receive either drug to see which better controls the virus and normalizes liver enzymes. The…

This study tests a new biologic drug called HH-006 in 45 adults with chronic hepatitis B. Participants receive injections for 48 weeks, and researchers track how well the drug lowers hepatitis B surface antigen (HBsAg) levels. The goal is to see if the drug can control the infect…

This early-stage trial tests a new therapy called CRMA-1001, which uses epigenetic gene silencing to turn off the hepatitis B virus in the body. About 66 adults with chronic hepatitis B who are already on antiviral pills will receive one or more IV infusions of the therapy. The m…

This Phase 3 trial is testing a new drug called libevitug in 160 people with chronic hepatitis D, a serious liver infection. The goal is to see if libevitug can lower the virus in the blood and improve liver health. Participants receive the drug by IV infusion, and the study comp…

This study tests a therapeutic vaccine called TherVacB in 81 adults with chronic hepatitis B who are already on antiviral medication. The vaccine is given as a series of shots to boost the immune system and lower hepatitis B virus levels. The main goals are to check safety and se…

This study looks at whether a plant-based (vegan) diet can help children with autoimmune hepatitis achieve disease remission. Researchers will compare a vegan diet to a standard high-protein diet over 180 days in 40 newly diagnosed children. The goal is to see if diet changes can…

This study looks at whether starting hepatitis C treatment during pregnancy is feasible and acceptable for women who have used drugs. Fifty pregnant adults with hepatitis C will take glecaprevir-pibrentasvir daily for 56 days. Researchers will track how well participants stick to…

This study tests whether a combined computer- and counselor-delivered alcohol treatment program can help people who receive an early liver transplant for severe alcoholic hepatitis stay alcohol-free. Researchers will compare this program to standard care in 200 participants, trac…

This study tests whether a drug called chiglitazar, combined with anti-inflammatory and liver-protecting therapies, can improve liver health in people who have both MASH (a severe fatty liver disease) and type 2 diabetes. About 300 adults will receive either the drug combo or a p…

This phase 3 trial tests whether adding N-acetylcysteine or extending prednisolone treatment beyond the standard 30 days can improve outcomes for people with severe alcoholic hepatitis. About 477 participants will be enrolled. The goal is to see if these strategies increase the n…

This study compares two approaches for treating non-alcoholic steatohepatitis (NASH), a serious liver condition linked to obesity. Half of the 48 participants will receive vertical sleeve gastrectomy surgery along with lifestyle counseling, while the other half will get lifestyle…

This early-stage trial tests a lab-made antibody (HepB mAb19) in 15 people with chronic hepatitis D, a serious liver infection that requires hepatitis B to survive. The goal is to see if the antibody is safe and can lower virus levels, potentially reducing the risk of liver damag…

This study tests whether a low dose of digoxin, a drug normally used for heart problems, can help people with a severe type of fatty liver disease called NASH (also known as MASH). The trial will involve 144 adults with biopsy-confirmed NASH and liver scarring. Participants will …

This study tests an investigational drug called TGM-312-SC01, given as a shot, for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition. It first checks safety and drug levels in healthy adults, then in people with MASH. The trial is currently recrui…

This study tests a new drug called HU6 for people with MASH, a serious fatty liver disease. About 180 adults aged 30 and older will receive either HU6 or a placebo to see if the drug safely reduces liver fat. The trial lasts 26 weeks and focuses on safety and how well the drug wo…

This project aims to make hepatitis C testing and treatment easier for people who visit drug treatment clinics and needle exchange programs. Researchers will work with clinics across New South Wales, Australia, to help more people start treatment. The study includes up to 6,000 a…

This study compares two antiviral drugs, tenofovir alafenamide (TAF) and entecavir, in 140 adults with chronic hepatitis B. The goal is to see which one controls the virus better and causes fewer kidney problems. Participants take one pill daily for about a year.

This study tests whether a mobile app called HBVCare can help people with chronic hepatitis B take their medication regularly and attend follow-up visits. About 70 adults in Vietnam will either use the app or receive standard care. After 3 months, researchers will compare how wel…

This Phase 2 study tests an experimental drug called ALG-000184 against a standard hepatitis B medication (tenofovir) in 200 adults with chronic hepatitis B. Participants take one pill daily for 48 weeks. The main goal is to see if the new drug can lower hepatitis B virus levels …

This study tests whether adding belimumab to standard therapy can better control autoimmune hepatitis, a chronic liver disease. About 48 adults with active or stable disease will receive weekly injections for 72 weeks. The goal is to reduce liver inflammation and lower the need f…

This early-stage study is testing whether stem cells from donated umbilical cords are safe and can help people with liver damage from hepatitis B. About 20 adults with moderate to severe cirrhosis will receive the stem cell treatment. The main goal is to see if it improves liver …

This study tests if weight-loss surgery is better than standard medical treatment for making nonalcoholic steatohepatitis (NASH) with advanced liver scarring disappear without making the scarring worse. It involves 100 obese adults with NASH and significant liver fibrosis. Partic…

This program offers eltrombopag to patients with serious or life-threatening thrombocytopenia (low platelet counts) who have no other treatment options and cannot join a clinical trial. A licensed physician must request the drug, and the potential benefit must outweigh the risks.…

This study involves over 16,000 people with chronic hepatitis B across three hospitals. The goal is to increase the number of patients referred to liver specialists and started on antiviral treatment. Researchers will also track how antiviral therapy affects patients' quality of …

This early-stage trial tests an experimental drug called NNC0581-0001 in 48 adults with fatty liver and suspected liver inflammation. Participants receive three monthly injections of either the drug or a placebo. The main goal is to check safety and how the drug moves through the…

This study looks at whether closely monitoring patients with mild to moderate liver inflammation from cancer immunotherapy, and only giving steroids if needed, is as safe and effective as starting high-dose steroids right away. About 56 adults with grade 2 or 3 immune-related hep…

This study tests whether a daily nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein can improve liver function and quality of life in adults with liver disease from chronic hepatitis C. Over 12 weeks, 26 participants will take either the s…

This 5-year study tests whether dapagliflozin, a diabetes drug, can prevent serious liver complications in people with chronic hepatitis B and diabetes who already have early liver scarring. 412 participants will receive either dapagliflozin or a placebo daily. The goal is to see…

This study tests whether a daily injection of tesamorelin can safely reduce liver fat in adults with metabolic fatty liver disease (MASLD). About 120 participants will receive either the drug or a placebo for 52 weeks, along with lifestyle advice. The main goal is to measure chan…

This study tests a new tablet called CS060380 for adults with non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. About 120 participants will take either the drug or a placebo daily for 12 weeks. Researchers will measure changes in liver fat using MRI and track a…

This study looks at the best time to give hepatitis C medication to people without HCV who receive a kidney from an HCV-positive donor. One group starts the drug just before transplant and takes it for only 2 weeks; the other starts after transplant and takes it for 12 weeks. The…

This study tests whether a low dose of the thyroid hormone Synthroid can help treat nonalcoholic steatohepatitis (NASH), a serious liver condition common in Veterans. About 128 overweight or obese Veterans with NASH will take either Synthroid or a placebo daily for one year. The …

This study tests a single dose of a new antibody (HepB mAb19) in 37 adults with chronic hepatitis B who are already on standard antiviral pills. The main goal is to see if the antibody is safe and how long it stays in the body. It is an early-phase trial, so it focuses on safety …

This Phase 3 trial tests whether adding GST-HG141 (Neracorvir) to standard antiviral therapy can better suppress the hepatitis B virus in patients who haven't responded adequately to current drugs. About 526 adults with chronic hepatitis B will receive either the experimental dru…

This study tracks 500 people who received a heart transplant from a donor with hepatitis C. Researchers want to see if using these organs is safe and works well. They will measure cure rates for hepatitis C, organ rejection, and survival after one year.

This study tests whether adding N-acetylcysteine (NAC) to standard steroid treatment helps people with severe alcoholic hepatitis live longer and have fewer complications. About 390 adults aged 18-75 with a high Maddrey score will be enrolled. The main goal is to see if the combi…

This study tests whether hepatitis B immunoglobulin (HBIG) can help people with chronic hepatitis B stay virus-free after they've cleared the surface antigen (a key sign of cure). Researchers will give HBIG shots to 132 participants who already cleared the virus with standard the…

This early-stage study tests the safety of a new drug, Tune-401, in 36 adults with chronic hepatitis B. Participants must already be on standard antiviral medication. The goal is to see if Tune-401 is safe and how the body processes it, not yet to cure the infection.

This phase 3 study tests azvudine tablets in 120 people with chronic hepatitis B. The drug works by both fighting the virus and activating the immune system. Researchers will monitor viral load, liver function, and immune activity over 12 months to see if azvudine can help achiev…

This early-stage study tests a new medicine called SA1211 for chronic hepatitis B, a long-term liver infection. Researchers will check safety and how the body processes the drug in 80 healthy volunteers and people with hepatitis B. The goal is to see if it can help control the vi…

This study tests resmiterom, the first FDA-approved drug for MASH (a type of fatty liver disease), in 165 Pakistani patients. Researchers will check how safe it is and whether it improves liver health using non-invasive scans. The goal is to see if the drug works well in this spe…

This Phase 3 trial tests whether hydroxychloroquine, a drug used for malaria and autoimmune diseases, can improve nonalcoholic steatohepatitis (NASH), a type of fatty liver with inflammation. 210 adults with confirmed fatty liver and elevated liver enzymes will take either 200 mg…

This study looks at whether taking a specific gut bacterium (Bacteroides fragilis) along with branched-chain amino acids can help clear the hepatitis B virus in people with chronic infection. About 40 participants will receive this combo as an add-on to their usual antiviral trea…

This early study tests whether siplizumab, given at the time of liver transplant, can safely prevent the immune system from attacking the new liver. Up to 8 adults with autoimmune hepatitis or primary sclerosing cholangitis will receive two doses. The main goal is to check for se…

This study tests a new medicine, IBI362, in 165 adults with MASH, a serious fatty liver disease that can lead to scarring. Participants will receive either a low dose, high dose, or a placebo for 60 weeks. The main goal is to see if the drug can improve liver health without makin…

This study tests a new drug called UBT251, given as a weekly injection, for people with MASH (a serious fatty liver disease with scarring). 156 adults will be randomly assigned to receive one of three doses of UBT251 or a placebo for 48 weeks. The main goal is to see if the drug …

This study tests an experimental drug called HRS-5635, given alone or with other medications, in people with chronic hepatitis B. The goal is to lower or clear the hepatitis B surface antigen (HBsAg) from the blood, which could mean better long-term control of the virus. About 36…

This early-phase trial at the Cleveland Clinic is testing whether a form of hyaluronic acid (HA35) can help prevent muscle loss in people with alcoholic hepatitis. 54 participants will take either HA35 or a placebo capsule daily for 90 days. The study involves two in-person visit…

This Phase 2 trial is testing an experimental drug called F573 in 97 people with acute liver failure or acute-on-chronic liver failure. Participants receive daily injections of F573 or a placebo for 7 days. The main goal is to check safety and side effects, while also looking at …

This study tests whether lungs from donors with hepatitis B can be safely given to people who do not have hepatitis B. The donated lungs are treated with UV light during a special preservation process, and recipients receive antiviral drugs and antibodies to prevent infection. Tw…

This study tests whether taking a probiotic called Lactobacillus rhamnosus GG (LGG) for 6 months can help people with alcohol use disorder reduce heavy drinking and improve liver health. Researchers will compare the probiotic to a placebo in 60 adults who drink heavily. The goal …

This early study is testing whether HEPLISAV-B, a vaccine normally used to prevent hepatitis B, is safe for people who already have chronic hepatitis B. Ten adults on stable antiviral therapy will receive two vaccine shots and be monitored for side effects and immune responses ov…

This study tests if a tube-like device called a stent, placed through a scope, can reverse gastric bypass surgery in 20 people who have serious complications like low blood sugar, blockages, or liver problems. The goal is to see if the stent works as well as surgery to fix these …

This study tests a new medicine, LW231, in people with chronic hepatitis B. The goal is to see if it is safe and can lower the amount of virus in the blood. Some participants will get LW231 alone, others will get it together with standard antiviral pills. The trial involves about…

This study tests a drug called ADI-PEG 20 against a placebo in 60 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. Participants receive injections over 24 weeks, and doctors measure changes in liver fat using MRI. The goal is to see if the drug can …

This study looks at whether low-dose prednisolone (a steroid) can safely treat liver inflammation (hepatitis) caused by immune checkpoint inhibitors in cancer patients. Researchers will enroll 63 adults with grade 2 or 3 immune-related hepatitis and give them 0.5-1 mg/kg of predn…

This phase 2 trial tests a combination of an anti-PD-1 antibody, interferon, and standard antiviral drugs in 120 adults with chronic hepatitis B. The goal is to boost the immune system to clear the virus and achieve a functional cure, where the virus stays under control without l…

This pilot study tests a drug called Imdusiran (AB-729) in 10 people with chronic hepatitis B. Participants receive four injections over 24 weeks and undergo two liver biopsies to measure how the drug works inside the liver and how it affects the virus. The goal is to understand …

This phase 2 trial tests a new combination of an anti-PD-1 antibody (a type of immunotherapy) plus standard antiviral drugs in 120 adults with chronic hepatitis B. The goal is to achieve a functional cure, where the virus is no longer active and patients can stop medication. The …

This study is testing a drug called TAF (tenofovir alafenamide) in pregnant women with chronic hepatitis B. The goal is to see if taking TAF daily from week 28-32 of pregnancy until delivery can prevent the baby from catching the virus. Researchers will also check how the drug mo…

This phase IV trial will enroll 5,500 people with liver cirrhosis or chronic hepatitis B—conditions that raise liver cancer risk. Participants are randomly assigned to either standard ultrasound screening or a new blood test called GALAD, which measures three proteins. The goal i…

This large Australian study is testing whether offering a finger-stick point-of-care test for hepatitis C can increase diagnosis and treatment rates. Adults at risk for hepatitis C will be offered the rapid test at services they already use. Those who test positive for the virus …

This large Australian study is testing whether offering finger-stick point-of-care testing for hepatitis C in community settings—like drug treatment clinics, homeless shelters, and prisons—can increase the number of people diagnosed and linked to treatment. The study will include…

This study evaluates whether a blood test measuring polyreactive immunoglobulin G (pIgG) can more accurately diagnose autoimmune hepatitis (AIH) and distinguish it from other liver conditions. Researchers will collect blood samples from 400 adults undergoing liver biopsy for susp…

This study collects blood samples from healthy people, those with benign diseases, and cancer patients to develop a multi-analyte blood test. The test looks for DNA methylation markers that may indicate the presence of various cancers, especially liver cancer. Researchers aim to …

This study is testing a new, non-invasive liver scan called iLivTouch to see if it can accurately detect a serious liver condition called MASH in people who have both type 2 diabetes and fatty liver disease. The scan measures liver inflammation, fat, and stiffness without any nee…

This study is collecting blood samples from 575 adults with fatty liver disease to find new, noninvasive tests that can detect liver scarring (fibrosis). Currently, doctors rely on a painful liver biopsy to check for scarring, but this research aims to replace that with a simple …

This study is testing a new, non-invasive MRI scan (called cT1) to see if it can accurately diagnose NASH, a serious liver disease. Currently, doctors need to take a small sample of liver tissue with a needle (biopsy) to confirm the diagnosis. The study will compare the MRI resul…

This study is looking at whether a blood test called the Enhanced Liver Fibrosis (ELF) test can find early signs of fatty liver disease in people who are at high risk, such as those with diabetes, high blood pressure, or heart disease. Researchers will review medical records of 3…

This study is testing a new rapid diagnostic device called TruPlex that can detect HIV, Hepatitis B, and Syphilis from a small blood sample. Researchers will enroll 1000 adults at risk for these infections to see how accurate and easy the test is to use in clinics and point-of-ca…

This study tests whether a special ultrasound done during an endoscopy can accurately detect liver scarring in people with obesity and suspected non-alcoholic fatty liver disease. Researchers will compare this new method to standard tests and liver biopsy in 150 adults. The proce…

This study looks at whether magnetic resonance elastography (MRE), a special type of MRI, can accurately measure liver scarring (fibrosis) in people with chronic hepatitis B. Researchers will compare MRE results to standard liver biopsies in 600 adults. If MRE works well, it coul…

This study is testing whether measuring spleen stiffness with a special ultrasound probe can detect advanced liver scarring in people with metabolic fatty liver disease (MASLD). Researchers will follow 500 adults for up to several years to see if the test predicts serious liver p…

This study aims to see if a dried blood spot test can effectively screen drug users for hepatitis B, hepatitis C, and AIDS. Researchers will enroll 500 former or active drug users. The goal is to find a simpler way to detect these infections in a hard-to-reach population.

This study is testing whether combining new blood tests and stool analysis can detect liver fibrosis earlier than current methods. Researchers will follow 1200 adults referred to a community liver clinic. The goal is to identify advanced liver disease sooner and reduce unnecessar…

This study is testing a new medical device called MagIA IBC that uses a single drop of blood from a finger prick to screen for HIV, hepatitis B, and hepatitis C at the same time. Researchers will enroll 252 adults who are known or suspected to have one of these infections. The go…

This study tests a new device called MagIA H3S that can screen for HIV, hepatitis B, hepatitis C, and syphilis using a single blood sample. Researchers will enroll about 2,950 people in Ivory Coast and Kenya to see how accurate the device is compared to standard lab tests. If it …

This pilot study is testing a new Thermoacoustic Enhanced Ultrasound device to measure fat in the liver. Researchers will compare the device's readings to the gold-standard MRI measurement in 49 adults with fatty liver disease. The goal is to develop a more accessible and afforda…

This study is testing a new way to measure liver scarring using an endoscopic ultrasound with special software. About 300 adults with suspected liver disease will undergo this new scan, a standard liver biopsy, and another non-invasive test. The goal is to see if the new techniqu…

This study tests whether a 'practice coaching' program can help opioid treatment clinics offer more HIV and hepatitis C testing to their patients. Clinics are randomly assigned to receive either coaching focused on HIV testing, coaching that adds hepatitis C testing, or just info…

This trial tests whether a mobile app called Wellnuts can help healthy adults aged 25–65 in Hong Kong become more aware of their health risks and take action. Participants use the app to assess their risk for conditions like diabetes, heart disease, and certain cancers, and recei…

This study combines peer navigation (trained community members) with mobile health tools to help gay, bisexual, and transgender people in rural Appalachia access HIV, STI, and hepatitis C testing and prevention services. About 141 participants will be split into two groups: one g…

This pilot study tests whether a peer-driven program can help people who inject drugs in Baltimore reduce their risk of HIV, hepatitis C, and overdose. Researchers will identify high-risk injection settings and train peers to promote safer practices, like carrying naloxone and av…

This study tests whether teaching Black male caregivers how to talk about sexual health can help protect Black girls aged 14-18 from HIV, other sexually transmitted infections, and sexual violence. The program involves 612 pairs of girls and their male caregivers. Researchers wil…

This study tests a program called Mobile Enhanced Prevention Support (MEPS) for people recently released from jail or prison who have substance use disorders. The program pairs participants with a peer mentor, offers cash incentives for using health services, and provides a smart…

This early-phase study tests whether anakinra, a drug that blocks inflammation, can make the heart more sensitive to inotropes (medicines that strengthen heart contractions) in people with end-stage heart failure. If successful, patients might need lower, safer doses of inotropes…

This study is testing whether a time-restricted eating plan (eating only during an 8-10 hour window each day) combined with a healthy plant-based diet is safe and doable for people with liver cancer, cirrhosis, or fatty liver disease. Fifty overweight or obese adults will either …

This study compares a Mediterranean diet to a Western diet to see which one better reduces fatigue in people with autoimmune hepatitis. About 48 adults will try both diets in a random order. Researchers will measure changes in fatigue and quality of life using a standard question…

This study is building a large collection of blood, saliva, urine, stool, and tissue samples from people who are at increased risk of cancer, including those with genetic predispositions, survivors of childhood or adult cancer, or those with precancerous conditions. The goal is t…

This study aims to learn more about liver diseases like hepatitis B, C, and D by observing up to 8,050 participants over time. Participants will have yearly check-ups, blood and urine tests, and liver ultrasounds. Some may be offered experimental treatments if they qualify. The g…

This study looks at whether a rapid fingerstick test that gives results in 10-20 minutes can help more people get screened for HIV, hepatitis C, and syphilis during mobile clinic visits. About 200 patients of the WVU Street Medicine team can choose the rapid test, a traditional b…

This study is testing whether a quick finger-stick test can help find more people with hepatitis C and get them into treatment. About 60,000 adults at risk for hepatitis C will take the test at clinics, shelters, or prisons. The study itself does not provide treatment, but will c…

This study follows 490 adults with a past hepatitis B infection who need immune-suppressing treatments. Researchers will monitor bone, kidney, and metabolic health over 4 years to understand the long-term side effects of antiviral drugs. The goal is to create better safety guidel…

This trial asks whether fructose, a sugar found in fruit and processed foods, causes more liver inflammation in people with MASH (a serious fatty liver disease) than in those with milder fatty liver or no liver disease. Over four weeks, participants follow a low-sugar diet and th…

This study follows 250 people newly diagnosed with HIV and 161 healthy volunteers over five years to see who develops metabolic fatty liver disease (MASLD). Researchers use annual blood tests, ultrasounds, and FibroScans to measure liver fat and stiffness. The goal is to uncover …

This study follows 1500 Chinese adults with chronic hepatitis B, nonalcoholic fatty liver disease, or both, to see how having both conditions changes the risk of serious liver problems like cirrhosis, liver failure, and liver cancer. Researchers will track who develops these comp…

This 10-year observational study follows 20,000 Chinese adults with non-alcoholic fatty liver disease (NAFLD) or its more severe form, NASH. Researchers aim to measure how common these conditions are and how they progress over time. By collecting medical data and blood samples, t…

This study tests a smartphone app designed to teach emergency room patients about hepatitis C (HCV) and help them connect to follow-up care. Researchers will enroll 308 HCV-positive patients at an urban ER. The app provides personalized information on liver health and care option…

This study aims to find undiagnosed cases of advanced liver fibrosis and viral hepatitis B and C in the general population of Seine Saint Denis, France. Using a combination of rapid diagnostic tests and a portable liver stiffness scanner (FibroScan), researchers will screen 600 a…

This study creates a large database and biobank of people with nonalcoholic fatty liver disease (NAFLD), a condition where fat builds up in the liver. Researchers will collect medical data and biological samples over time to study how the disease develops, progresses, and respond…

This study looks at whether certain gene variations in the donor and the recipient influence how much fat builds up in the new liver after a living-donor transplant for MASH-related cirrhosis. Researchers will compare genetically related and unrelated donor-recipient pairs to sep…

This study aims to find out how many people with hepatitis B also have hepatitis delta, a more serious liver infection. Researchers will test 244 adults in hospitals, addiction clinics, and prisons in Bergamo, Italy. The goal is to improve detection and understand the true burden…

This early-stage trial is testing a new drug called BI 3804379 in healthy adults to see if it is safe and how the body processes it. About 106 healthy men and women aged 18 to 65 will receive either the drug or a placebo as a shot under the skin. The study focuses on side effects…

This study aims to find out how often people with chronic hepatitis B also have hepatitis D, and which types of the virus are most common. Researchers will interview about 2,400 participants and take blood samples to look for links with vaccination history, lifestyle, and other f…

This study looks at how gut bacteria produce certain chemicals that might worsen fatty liver disease (MASLD). Researchers will collect stool, blood, and urine samples from 24 people with the condition and healthy volunteers. They aim to identify which bacteria are responsible for…

This study uses a device called FibroScan to measure liver stiffness and fat content in people with liver disease. The scan is non-invasive, like an ultrasound, and takes only a few minutes. Researchers aim to build a large database of these measurements to help improve future di…

This early-phase study tests a new way to use PET scans to measure inflammation in both the liver and brain at the same time. Researchers will scan 12 adults with fatty liver disease using two different tracers (18F-FDG and 18F-DPA-714) to see if the new method can reliably detec…

This study in South-East Austria looks at past lab results to find people with hepatitis B, C, or D who may not know they have it. Researchers will invite these individuals to a clinic to discuss treatment options. The goal is to connect them to care and track how many get cured,…

This study looks at liver inflammation (hepatitis) that can occur in cancer patients treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers aim to describe the different patterns of liver injury and how they respond to treatment. By collecting real-world …

This study looks at whether new MRI techniques can spot NASH, the serious form of fatty liver disease, without needing a liver biopsy. Researchers will scan 110 adults who already need a biopsy to see if the MRI can match the biopsy results. If successful, it could lead to a safe…

This study will screen 2,000 people with HIV for fatty liver disease using a painless ultrasound technique. The goal is to catch liver problems early and improve long-term care. Researchers will also track how different HIV medications affect liver health.

This study will follow 20,000 elderly people with fatty liver disease to learn what factors affect their health. Researchers will look at lifestyle, genetics, and environment to understand how the disease progresses. The goal is to create better risk assessment tools and preventi…

This early-stage study is testing a single dose of the drug miricorilant in 15 adults with MASH (a type of fatty liver disease) or MASH with cirrhosis. The main goal is to see how the body processes the drug and whether it is safe. This is not a test of whether the drug works, bu…

This study is creating a large collection of blood samples and health data from 3500 people with hepatitis B, including those who have already cleared the virus. Researchers will use these samples to look for viral RNA patterns that could signal a functional cure. No new treatmen…

This study looks at how inflammation and liver repair differ in people with alcoholic hepatitis versus those with alcoholic cirrhosis or healthy livers. Researchers will collect blood, liver tissue, and fluid samples from 450 participants. The goal is to better understand what dr…

This study is looking at 1,000 liver transplant recipients to see if testing their blood, urine, and tissue samples can detect early signs of chronic kidney disease, acute rejection, or hepatitis C. The goal is to find simple biomarkers that could lead to earlier treatment and fe…

This study is observing heavy drinkers with jaundice to learn more about alcoholic hepatitis, a serious liver condition. Researchers will track survival and liver function over 12 months, and collect genetic samples to better understand the disease. The goal is to improve diagnos…

This study will follow 10,000 people in Australia who have chronic hepatitis B to see how well they are connected to care and treatment. Researchers will collect information from clinics across the country to understand who is getting treated and what their health needs are. No n…

This study looks at genetic changes in natural killer (NK) and B cells—key immune cells—in people with chronic hepatitis B. Researchers want to understand why these cells don't work properly during long-term infection. The study will analyze blood samples from 140 adults with chr…

This study follows 390 adults in Zambia with hepatitis B, some also with HIV, to see how their liver and immune system change over time. Participants join when diagnosed or starting standard antiviral treatment and are monitored for years. The goal is to learn more about the dise…

This study looks at whether people with chronic hepatitis B who have undetectable virus levels in their blood also have undetectable levels in other body fluids like saliva or semen. Researchers will compare treated patients with suppressed virus to untreated patients with active…

This study is not testing a new drug or treatment. Instead, researchers want to make sure their lab tests and equipment give accurate and repeatable results when studying conditions like obesity, diabetes, heart disease, and bone loss. Up to 100 healthy volunteers and people with…

This early-stage study tests an experimental drug called HEC169584 in 96 healthy adults aged 18 to 45. The main goal is to check if the drug is safe and how the body processes it, not to treat any disease. Results will help guide future studies for non-alcoholic steatohepatitis (…

This study looks at how the hepatitis B vaccine triggers T cells, a key part of the immune system. Researchers will test blood from 115 healthy adults 5 to 10 weeks after vaccination to see if they have T cells that recognize the hepatitis B virus. The goal is to understand why s…

This study tracks the safety of the liver drug Rezdiffra (resmetirom) in women with NASH who take it while pregnant or breastfeeding. Researchers will follow about 10 women and their infants up to 12 months old to check for birth defects, growth problems, and other health issues.…

This study looks at why the hepatitis B virus (HBV) stays in the liver for so long, even with treatment. Researchers will use a gentle needle technique to take small liver samples from 100 adults with chronic HBV. They want to see how the virus and the immune system interact insi…

This study aims to understand how liver diseases like fatty liver, hepatitis B, fibrosis, and cirrhosis develop by analyzing individual liver cells and their spatial organization. Researchers will collect blood and discarded liver tissue from 240 patients undergoing surgery or bi…

This study looks at immune cells from lymph nodes, tonsils, and liver tissue of people with chronic hepatitis B. Researchers want to understand how the germinal centers—the parts of the body that train immune cells—respond to the virus. By analyzing these tissues, they hope to le…

This study looks back at medical records of 2,000 people with hepatitis C who took an 8-week course of glecaprevir/pibrentasvir (G/P). The goal is to see how safe and effective the treatment is for those also taking prescription or illegal drugs. Researchers will track side effec…

This study is recruiting 710 adults with fatty liver disease or alcohol-related liver disease, with or without cirrhosis, to understand why some develop liver cancer. Researchers will analyze genetic markers, immune factors, and imaging data from routine liver biopsies and blood …

This study looks at how androgens (a type of sex hormone) might affect fatty liver disease in young women. Researchers will compare changes in liver fat and stiffness over time in 150 women with and without PCOS. The goal is to understand the connection, not to test a treatment.

This study tests whether a very brief, persuasive message—delivered by a video or a counselor—can increase HIV and hepatitis C testing among emergency room patients who initially said no. About 2,000 adults who speak English or Spanish and haven't been tested in the past year wil…

This study follows 240 adults with NASH-related cirrhosis to find better ways to detect early signs of liver failure, such as internal bleeding, fluid buildup, or confusion. Researchers will track health records and exams over time to improve monitoring. The goal is to understand…

This study looks at how common certain infections are among 250 asylum seekers living in reception centers in Italy. Participants must be adults who arrived in Italy between 2 and 36 months ago. The goal is to better understand infection rates to improve health screening and care…

This study looks at the link between gum (periodontal) disease and hepatitis B+D infection, and whether the drug bulevirtide changes that relationship. Researchers will measure inflammation markers in saliva and gum fluid from 25 adults: those with hepatitis B+D on bulevirtide, t…

This study observes 160 cancer patients to understand why some develop liver injury from checkpoint inhibitor drugs. Researchers will track blood markers and genetic factors to identify who is at risk. No new treatment is tested; the goal is to improve diagnosis and monitoring.

This study looks at the gut bacteria of 3000 adults with chronic liver diseases like autoimmune hepatitis and fatty liver. Researchers want to find specific bacteria linked to each disease to better understand how the gut and liver interact. This is an observational study, not a …

This study follows 3,000 adults with cirrhosis or who have had a liver transplant at a French hospital. Researchers will track survival and complications like bleeding or infections to learn how to improve patient care. The goal is to collect data and samples to better understand…

This study is re-examining 1,400 adults in Stockholm to find early signs and risk factors for heart, lung, and liver diseases. Participants will get advanced scans, blood tests, and questionnaires. The goal is to better understand how these diseases develop and how to predict the…

This study looks at the genes in colon polyps from people with MASH (a type of fatty liver disease) compared to those without fatty liver. Researchers want to find specific gene patterns that might signal higher risk. About 100 adults already scheduled for polyp removal will dona…

This study collects DNA from 1200 patients receiving routine care at the University of Chicago. Researchers look for genetic differences that might affect how well a drug works or how likely it is to cause side effects. The goal is to see if giving this genetic information to doc…

This study is testing a mobile app called ePro-Diary HDV for people with hepatitis Delta, a rare but serious liver disease. The app helps patients track their health, communicate with doctors, and remember appointments. Researchers want to see if using the app helps patients atte…

This early study tests a single dose of the drug pevifoscorvir in 30 people with chronic hepatitis B, some with kidney problems and some with healthy kidneys. Researchers want to see how kidney function affects drug levels and safety. The goal is to learn how to dose the drug pro…

This study looks at how the drug bulevirtide changes gut bacteria and bile acids in people with hepatitis delta (a serious liver infection). Researchers will follow 20 patients for 48 weeks, collecting stool and blood samples to see how these changes relate to liver health. The g…

This study is a long-term project that collects health information from 30,000 HIV patients at 15 clinics in France. The goal is to track how well HIV treatments are working, monitor changes in the disease over time, and understand related health issues like hepatitis C. No new t…

This study collects blood and tissue samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, such as cell clusters and mouse tumors, to study these diseases and test new treatments. The goal is to improve unders…

This study looks at bacteria found in the liver, blood, and stool of 50 people with severe alcoholic hepatitis. Researchers want to see if these bacteria are linked to how well patients respond to treatment and their overall survival. The goal is to find new ways to treat this se…

This early-stage study tests a single dose of the drug pevifoscorvir sodium in 16 adults: 8 with moderate liver impairment and 8 healthy volunteers. Researchers want to see how the drug is processed in the body and if it is safe. The goal is to gather information for future dosin…

This study from Mayo Clinic looks at how inflammation in fat tissue may affect the liver in people with severe obesity. Researchers will measure liver stiffness and fat tissue markers in 60 adults before they have weight-loss surgery. The goal is to better understand why some peo…

This study will test 10,000 people in Cambodia for 57 different infectious diseases, including dengue, flu, and malaria. Researchers want to understand how these diseases spread and who is at risk. The goal is to give local health authorities the information they need to create b…

This early-stage study tests a new drug called ECC4703, being developed for a serious fatty liver condition (MASH). Researchers want to see how taking the drug with or without food changes the amount that gets into the blood. 72 healthy adults will receive a single dose of the dr…

This study looks at how common non-alcoholic fatty liver disease (NAFLD) and its more serious form, NASH, are in Olmsted County, Minnesota. Researchers will follow 800 adults over time to better diagnose these conditions and see how they affect long-term health, including risks f…

This study looks at how the immune system fights hepatitis D in people who also have hepatitis B. Researchers will measure special immune cells (T cells) in 192 adults before and after 12 months of treatment with the drug bulevirtide. The goal is to see if these immune responses …

This study looks at how tiny communication points inside liver cells (called MAMs) change in people with a fatty liver disease called MASH. Researchers will collect liver and blood samples from 20 adults having weight-loss surgery. The goal is to understand what goes wrong in the…

This observational study aims to develop a rapid T-cell test to help manage patients with chronic hepatitis B (HBV) and hepatitis B/D (HBV/HDV) co-infection. Researchers will analyze immune responses in 300 adult patients to understand how T-cells react to the viruses. The goal i…

This study looks at how to get more people in Canadian federal prisons to use needle exchange programs, which can help stop the spread of HIV and hepatitis C. Researchers will work in nine prisons, including five women's prisons, to find out what helps or hinders program use and …

This study looks at DNA methylation patterns in 100 people with severe liver failure caused by hepatitis B. Researchers aim to build a model that predicts how the disease will progress, which could help doctors make better treatment decisions. The study is observational and does …

Acute alcoholic hepatitis is a serious liver condition with a high risk of death, but current prediction tools are limited. This study will analyze data from 1,400 patients to find more accurate markers of prognosis. By integrating clinical, lab, and tissue information, researche…

This study collects blood and urine samples from 500 people with alcoholic liver disease, heavy drinkers without liver disease, and healthy non-drinkers. The goal is to create a biorepository that researchers can use to study biomarkers and improve understanding of the disease. P…

This study compares immune cell function in 30 healthy volunteers, heavy drinkers, and people with alcoholic hepatitis. Researchers will analyze blood samples to measure how mitochondria (the cell's powerhouses) work and how cells respond to inflammation. The goal is to better un…

This study looks at how certain genes increase the risk of liver cancer (hepatocellular carcinoma) in people with nonalcoholic fatty liver disease (NAFLD). Researchers will follow 500 adults aged 45-75 with NAFLD to understand how genetic factors and lifestyle interact. The goal …

This study uses tiny, lab-grown liver models (organoids) made from patient cells to understand how a specific gene variant (I148M of PNPLA3) contributes to non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. Researchers will expose these mini-livers to fatty acid…

This study aims to identify specific blood markers that can distinguish hepatitis caused by immune checkpoint inhibitors from other types of autoimmune hepatitis. Researchers will collect blood samples and liver tissue from 60 adults receiving immunotherapy. The goal is to improv…

This study follows 33,000 adults with chronic hepatitis B to see how well different antiviral medicines work over up to 5 years. Researchers will compare treatments like entecavir, tenofovir, and peginterferon to find which ones best prevent liver cancer and other serious liver p…

This study will follow 5000 people with chronic hepatitis B who are not on antiviral treatment, aged 1 to 80, for several years. Researchers will take blood samples every six months to track how the immune system responds to the virus as patients age. The goal is to better unders…

This study looks at whether giving out special syringes with less leftover space (low dead-space) can help reduce the spread of HIV and hepatitis among people who inject drugs. Researchers will talk with participants and track their health in several countries. The goal is to fin…

This is the first time BAR502, an experimental drug for NASH (a serious liver condition), is being tested in humans. The study involves 52 healthy adults to check the drug's safety, tolerability, and how the body processes it. Participants receive either a single dose or multiple…

This study interviews 25 people with MASH (a fatty liver disease linked to metabolism) to learn about their expectations, attitudes, and unmet needs before and after joining a special heart-liver program. Participants will have two private interviews. The goal is to improve care …

This study looks at medical records from 15,000 people to see how chronic liver diseases (like hepatitis, fatty liver, and cirrhosis) are linked to other health problems. Researchers will track new cases of liver cancer and complications over time. The goal is to better understan…

This study looks at the immune cells inside the liver of people with non-alcoholic fatty liver disease (NAFLD). The goal is to find differences between those with simple fatty liver and those with the more serious form, NASH, which can lead to cirrhosis and liver cancer. Research…

This real-world study is following 15,000 people with chronic hepatitis B across 200 hospitals in China. Researchers are comparing how well different antiviral drugs and interferon injections work to prevent liver cancer and improve long-term health. The goal is to find the best …

This study is collecting blood, urine, and stool samples from 500 children with autoimmune diseases and healthy controls. Researchers will analyze these samples to find molecular patterns that could help diagnose these conditions and guide treatment decisions. The goal is to crea…